Drugs / Custodiol
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03082716 | Mar 2016 → Mar 2018 | congenital heart disease | King Faisal Specialist Hospital & Research Center | Completed | Met primary |
| Phase 2 | NCT01444235 | Mar 2011 → May 2012 | coronary artery disorder | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01401140 | Jun 2010 → Mar 2012 | coronary stenosis | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02327611 | Feb 2015 → Jan 2018 | aortic aneurysm | Scientific Institute San Raffaele | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT07381530 Comparator | Dec 2024 → Dec 2026 | congenital heart malformation | Dr. F. Köhler Chemie GmbH | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT06032195 Comparator | Aug 2023 → Jan 2027 expected | — | Dr. F. Köhler Chemie GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT02869022 Comparator | Jul 2016 → Sep 2019 | heart failure | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02098772 Comparator | May 2014 → Nov 2018 | aortic valve disorder, coronary artery disorder | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Custodiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03082716 ↗ |
| Known as | histidine-tryptophan-ketoglutarate | “Custadiol (histidine-tryptophan-ketoglutarate), an alternative, may have some advantages but is potentially less effective at myocardial protection.” PMID 37798628 ↗ Oct 2023 |
| Route | Other | “via an anterograde approach” NCT01401140 ↗ |